Use of Cysteamine in the Treatment of Cystinosis

Cystinosis Clinical Trial

Official title:

Use of Cysteamine in the Treatment of Cystinosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00359684
• Other study ID #: 780093
• Secondary ID: 78-HG-0093
• Status: Recruiting
• Start date: January 4, 1979

Study information

• Verified date: May 6, 2024
• Source: National Institutes of Health Clinical Center (CC)
• Contact: William A Gahl, M.D.
• Phone: (301) 402-2739
• Email: gahlw[@]mail.nih.gov
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Cystinosis is an inherited disease resulting in poor growth and kidney failure. There is no known cure for cystinosis, although kidney transplantation may help the renal failure and prolong survival. Both the kidney damage and growth failure are thought to be due to the accumulation of the amino acid cystine within the cells of the body. The cystine storage later damages other organs besides the kidneys, including the thyroid gland, pancreas, eyes, and muscle.

The drug cysteamine (Cystagon; ProCysBi) is an oral medication given to patients with cystinosis prior to kidney transplantation. The drug works by reducing the level of cystine in the white blood cells and muscle tissue. The drug may also decrease levels of cystine in the kidneys and other tissues.

This study has several goals:

1. Long-term surveillance of cysteamine treated patients.

2. Detection of new non-kidney complications of cystinosis.

3. Maintenance of a patient population for genetic testing (mutational analysis) of the cystinosis gene.<TAB>

...

Description:

Patients with nephropathic cystinosis have been treated with the cystine-depleting agent cysteamine since 1978. This therapy prevents or delays renal deterioration, improves growth, and depletes parenchymal tissues of cystine. Based largely upon data produced through this protocol, the Food and Drug Administration approved cysteamine bitartrate for use in cystinosis patients on August 15, 1994. Cysteamine is available as CystagonR through Mylan Pharmaceuticals in 50 mg and 150 mg capsules and as ProcysbiR in 75 mg capsules. By virtue of the current protocol, patients are admitted to the NIH Clinical Center for investigations every two years, except for cases of great interest or urgency. On each 1-3 day admission, a battery of tests is performed and the adequacy of cystine depletion by cysteamine is monitored. This protocol demonstrates the course of cystinosis patients treated with cysteamine, describes new complications of the disorder in poorly treated adults, and maintains NHGRI expertise in the field. Its monitoring and followup of patients over the course of 3 decades represents an invaluable contribution to our understanding of the natural history of this rare disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 330
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Week to 115 Years

Eligibility

• INCLUSION CRITERIA:

Diagnosis of cystinosis, whether classical or one of the variants with later onset or no renal complications.

Patients will be diagnosed as having cystinosis based upon a leucocyte cystine content greater than 1 nmol half-cystine/mg protein (normal, less than 0.2) and a typical clinical course.

EXCLUSION CRITERIA:

Inability to travel to the NIH.

Age less than one week.

Nonviable neonates and neonates of uncertain viability will be excluded.

Related Conditions & MeSH terms

• Cystinosis

Intervention

Drug:
• Cysteamine
Cystine-depleting agent

Locations

Country	Name	City	State
United States	National Institutes of Health Clinical Center	Bethesda	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Human Genome Research Institute (NHGRI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Florenzano P, Ferreira C, Nesterova G, Roberts MS, Tella SH, de Castro LF, Brown SM, Whitaker A, Pereira RC, Bulas D, Gafni RI, Salusky IB, Gahl WA, Collins MT. Skeletal Consequences of Nephropathic Cystinosis. J Bone Miner Res. 2018 Oct;33(10):1870-1880. doi: 10.1002/jbmr.3522. Epub 2018 Jul 20. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serve as a source of knowledge and advice for individual cystinosis patients and for the community at large	Serve as a source of knowledge and advice for individual cystinosis patients and for the community at large	Follow-up can occur every two years

External Links

•   NIH Clinical Center Detailed Web Page